Almirall partners with US firm on actinic keratosis candidate

12 December 2017

Spain’s largest drugmaker Almirall (ALM: MC) has linked up with US biopharma company Athenex (Nasdaq: ATNX) to further develop and commercialize KX-391 for the treatment of actinic keratosis and other skin conditions.

Subject to the terms and conditions of the license agreement, Athenex will grant to Almirall an exclusive license under the Athenex IP to research, develop and commercialize KX2-391 in the USA and European countries, including Russia.

Despite the fact that the deal – announced late on Monday - will net Athenex at last $55 million, the US firm’s shares were down 9.7% at $14.41 at close of trading, though recovered slightly to $14.68 after-hours. Almirall was barely changed this morning,

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK